Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy

Shogo Ohkoshi, Masahiko Yano, Yasunobu Matsuda

Shogo Ohkoshi, Department of Internal Medicine, School of Life Dentistry at Niigata, The Nippon Dental University, Chuo-ku, Niigata 951-8580, Japan

Masahiko Yano, Yasunobu Matsuda, Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences Niigata University, Niigata 951-8520, Japan

Author contributions: Ohkoshi S wrote the paper; Yano M performed research; Matsuda Y analyzed the data.

Supported by Grant-in-Aid for Scientific Research (C) (22590722 for Ohkoshi S) from the Japan Society for the promotion of Science (JSPS).

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Shogo Ohkoshi, MD, PhD, Professor of Internal Medicine, School of Life Dentistry at Niigata, The Nippon Dental University, 1-8Hamaura-Cho, Chuo-ku, Niigata 951-8580, Japan. okoshi@ngt.ndu.ac.jp
Telephone: +81-25-2118243
Fax: +81-25-2671582

Received: March 30, 2015
Peer-review started: March 31, 2015
First decision: May 18, 2015
Revised: May 30, 2015
Accepted: August 31, 2015
Article in press: August 31, 2015
Published online: November 14, 2015

Abstract
A well-known tumor suppressor, p21, acts paradoxically by promoting tumor growth in some cellular conditions. These conflicting functions have been demonstrated in association with the HBx gene and in hepatocarcinogenesis. The molecular behavior of p21 depends on its subcellular localization. Nuclear p21 may inhibit cell proliferation and be proapoptotic, while cytoplasmic p21 may have oncogenic and anti-apoptotic functions. Because most typical tumor suppressive proteins also have different effects according to subcellular localization, elucidating the regulatory mechanisms underlying nucleo-cytoplasmic transport of these proteins would be significant and may lead to a new strategy for anti-hepatocellular carcinoma (HCC) therapy. Chromosome region maintenance 1 (CRM1) is a major nuclear export receptor involved in transport of tumor suppressors from nucleus to cytoplasm. Expression of CRM1 is enhanced in a variety of malignancies and in vitro studies have shown the efficacy of specific inhibition of CRM1 against cancer cell lines. Interestingly, interferon may keep p21 in the nucleus; this is one of the mechanisms of its anti-hepatocarcinogenic function. Here we review the oncogenic property of p21, which depends on its subcellular localization, and discuss the rationale underlying a new strategy for HCC treatment and prevention.

Key words: p21; Tumor suppressors; Oncogene; Subcellular localization; Hepatocellular carcinoma; HBx; Nucleo-cytoplasmic export; Chromosome region maintenance 1; Selective inhibitors of nuclear export; Interferon

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: A well-known tumor suppressor, p21, can act paradoxically by promoting tumor growth, depending on its subcellular localization. Nuclear p21 may inhibit cell proliferation while cytoplasmic p21 may be associated with anti-apoptotic and oncogenic functions.
These conflicting roles are reviewed in the context of the HBx gene and hepatocarcinogenesis. Because most tumor suppressors act in a similar manner to p21, regulation of their nucleo-cytoplasmic export, which is mainly effected via chromosome region maintenance 1, may be a basis for developing a new strategy for anti-hepaticellular carcinoma therapy.

Ohkoshi S, Yano M, Matsuda Y. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. World J Gastroenterol 2015; 21(42): 12150-12156 Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i42/12150.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i42.12150

INTRODUCTION

Primary liver cancer is the 5 th most common cancer in men and the 7 th in women, with high mortality worldwide; therapeutic options for cure are urgently needed[1,2]. Hepatocellular carcinoma (HCC) accounts for most primary liver cancer. Although there is a geographic difference in incidence of HCC caused by some etiological variation, the major etiological agents are hepatitis B (HBV) and hepatitis C virus (HCV) infection. Once these viruses infect liver, they ingeniously evade host immune surveillance and induce chronic necroinflammation, leading to fibrosis and, ultimately, liver cirrhosis. Hepatocytes, via their innate regenerative capacity, continue to proliferate in order to compensate for the necrotic tissue. Genetic alterations continuously accumulate during these processes, resulting in pathogenic liver changes such as cirrhosis from which HCC frequently arises[3]. Once HBV-related cirrhosis is established, HCC develops at an annual rate of about 4% in Japan, for example[4].

Several lines of evidence support the direct involvement of HBV in the transformation processes. HBV is like a retrovirus in that it integrates into the host genome, causing chromosomal abnormalities. In addition, the HBx gene acts like an oncogene by trans-activating many genes involved in cellular transformation.

No common molecular mechanisms that account for the extremely complex process of hepatocarcinogenesis have yet been elucidated. Genetic alterations reported have been heterogeneous, involving abnormalities of many signal transduction pathways[2,3]. However, a fundamental abnormality in hepatocarcinogenesis, like other malignancies, is deregulation of the cell cycle. The main regulators of the cell cycle are cyclin-dependent kinase inhibitors (CDKI), such as p21, p27, and p16, widely known as tumor suppressors. However, it is noteworthy that these tumor suppressors can function in an oncogenic manner depending on their precise intracellular localization. In this review, we explore the relevance of the intracellular localization of p21, in particular, and its function, to highlight the possibility that regulating the intracellular localization of tumor suppressors may be a potential future anti-HCC strategy in the context of both directly-killing tumor cells and preventive role.

P21 AS AN ONCOGENE

First identified in 1993[5,6], p21 is a universal CDKI that causes G1 growth arrest downstream of p53[7,8]. p21 binds to CDKs and inhibits the kinase activity, leading to growth arrest at specific stages in the cell cycle[9,10]. p21 also induces cellular differentiation and senescence.

Although p21 is one of the major tumor suppressors, it also can promotes oncogenesis. High expression of p21 is associated with poor prognosis of cancer[11-13]. Although mutation of the p21 gene has been reported in bladder cancer[14], most reported studies failed to show the loss-of-function mutations of p21[15-17]. These results suggest that p21 may not be a classical tumor suppressor.

Experimental results of using genetically-engineered mice also support conflicting functions of p21. Spontaneous tumors occurred in p21-deficient mice, providing evidence that p21 is a tumor suppressor[18]. p21 also causes genomic instability[19]. However, the timing of tumor formation in p21-deficient mice was later than p53-deficient mice[20]. Moreover, the occurrence of lymphoma was suppressed when p21-deficient mice were crossed with p53- or ATM-deficient mice[21,22]. This result indicates that p21 also acts in an oncogenic way in particular conditions, reflecting its versatile function[19]. In addition, mammary gland tumorigenesis was accelerated in mice in which p21 was overexpressed in cytoplasm[23], and the cyclin-binding motif of p21 has been reported to have a direct tumorigenic function[24].

HCC, HBX AND P21

There have been many reports regarding the expression of p21 in HCC tissues. p21 was found to be down-regulated in HCC tissues, demonstrating its tumor suppressing function[25-27]. Kao et al[28] also reported that p21 expression was observed in 37% of HCC tissues, regardless of p53 expression, and was an independent survival good prognosis factor. While most of the reports show that p21 acts as a tumor suppressor, expression levels of p21 in liver cirrhosis have been reported to be correlated with the cumulative incidence of the occurrence HCC[29] and to be dominant in cytoplasm when histology became more undifferentiated[30].

There are also some reported studies examining the relationship between HBV and p21. Some reports have shown that the HBx gene exerts oncogenic activity by suppressing p21 expression[31,32] and that HBx genes having core promoter mutations suppress p21 more effectively[33]. Inversely, HBx enhanced p21
ASSOCIATION BETWEEN MOLECULAR BEHAVIOR OF P21 AND ITS ONCOGENIC FUNCTION

What molecular behavior of p21 does correlate with its tumor-promoting function? It is well-known that p21 has not only inhibitory effects on cell cycle, but also has a promoting role. p21-associated CDKs exist in both active and inactive states[37]; p21 promotes the assembly of CDK4,6 and cyclin D and exerts oncogenic activity without inhibiting kinase activity[38]. Mantel et al[39] found a high level of induction of p21 in a myeloid cell line that was induced to proliferate by growth factors, p21 also induces nuclear retention of cyclin D1, inhibiting its cytoplasmic degradation[40]. p21 induces cell cycle progression in glioma[41] and in vascular smooth muscle cells[42] by promoting the formation of active cyclin-CDK complexes with PKC-alpha. Because the lymphoma observed in p21-deficient mice has high levels of apoptosis[21], the oncogenic activity of p21 may be closely associated with its anti-apoptotic function.

P21 has a dual function with regard to apoptosis. p21 halts the cell cycle and prevents apoptosis induced by genotoxic agents. This anti-apoptotic function of p21 may be associated with its oncogenic property. However, p21 acts as a pro-apoptotic in some conditions. Forced expression of p21 induces the apoptotic response against cisplatin in glioma[43] and in ovarian cancer[44]. p21 is a modulator of apoptosis in a p53-dependent or -independent manner[10]. Masgras et al[45] reported that cell-specific sensitivity to oxidative stress determined whether the cell was fated to undergo p21-induced cell death.

REGULATION OF THE SUBCELLULAR LOCALIZATION OF TUMOR SUPPRESSORS AND ITS POTENTIAL APPLICATION TO ANTI-HCC TREATMENT

Transport of macromolecules across the nuclear envelope occurs through nuclear pore complexes (NPC). Karyopherins, such as exportins and importins, are nuclear transport receptors that recognize nuclear localization signal (NLS) sequences, respectively, and transport cargo proteins at the NPC sites[55,57]. Subcellular localization of tumor suppressors is regulated by this nucleocytoplasmic transport system[55,56,58,59].

CRM1 (Exportin-1/chromosome region maintenance 1) is a major nuclear export receptor that forms NPC with nucleoporins, such as NUP214 and NUP88, transporting nuclear proteins with NES sequence to cytoplasm[55-59]. CRM1 is deeply involved in the mechanisms of cell proliferation by regulating the subcellular localization of tumor suppressors which have NES sequences, such as p53 and p21. For example, p53
return cytoplasmic p21 to the nucleus and contributed to the prevention of hepatocarcinogenesis \[36\]. This was also true of p53 that was bound to cytoplasmic HBx and returned to the nucleus after IFN-treatment \[76\] (Figure 1). These observations suggest that natural substances such as IFN may be involved in an innate carcinogenesis prevention mechanisms, possibly by regulating CRM1. In fact, CRM1 is involved in the cytoplasmic localization of STAT2, which shifts to the nucleus by the action of IFN \[77\]. In addition, IFN inhibits beta-catenin signaling through the up-regulation of the nuclear RanBP3 which is a nuclear export factor \[78\].

**FUTURE PERSPECTIVE**

Sorafenib is a tyrosine kinase inhibitor widely used for the treatment of advanced HCC, and many other molecular-targeted drugs are now in development \[79\]. However its effect is still limited in many patients and the appearance of drug-resistance is a significant problem. Regulation of CRM1 involves many genes and specific multiple pathways associated with nuclear-cytoplasmic export; a new therapeutic strategy could be based on these developing concepts. Because such regulation would normalize molecular changes caused by multiple genes, its use might not cause drug resistance, or even being suggested to reverse drug resistance \[55\]. Thus, combination of such regulation with specific inhibitor use might maximize the impact of treatment. While expecting some promising results of clinical trials, taking the molecular approach to explore innate mechanisms regulating nuclear-cytoplasmic distribution of tumor suppressors will become an intriguing theme for development of cancer prevention strategies. In particular, IFN might accumulates in the nucleus when poly (ADP-ribosyl)ation blocks its interaction with CRM1 \[60\], while interaction with SUMO (small ubiquitin-like modifier) promotes its export to cytoplasm by CRM1 \[61\]. p21 inhibits CRM1 by binding phosphorylated cyclin D, which promotes its nuclear accumulation \[40\].

Cancer cells use nucleo-cytoplasmic transport system for their proliferation and inhibition of apoptosis. CRM1 expression is enhanced in many cancer tissues. High expression of CRM1 in gastric, ovarian, and pancreatic cancers show poor prognosis \[62-64\]. The increase in CRM1 leads to cytoplasmic abundance of tumor suppressors and cell cycle regulators, which in turn results in their aberrant activation. Knock-down of CRM1 expression prevents nuclear export of p27, resulting in cell cycle arrest \[65\]. Specific suppression of CRM1 caused nuclear retention of p21 and induced apoptosis \[66\]. The cellular apoptosis susceptibility (CAS)/importin pathway was found to be enhanced in HCC, confirming the importance of the transport machinery \[67\].

Orally available selective inhibitors of nuclear export (SINEs) which specifically inhibit CRM1, have been developed in recent years \[58,59\]. SINEs specifically bind Cys528, located in NES-binding groove of CRM1, to promote nuclear retention of p53, p21, p27, Rb, and BRCA 1 \[68\]. The effects on hematologic malignancies of KPT-330, the most effective SINE, have been reported \[69-73\]. KPT-330 had anti-proliferative effects and induced apoptosis of an HCC cell line \[74\] in which p53-upregulated-modulator of apoptosis was markedly up-regulated; and this was shown to be one of the similar mechanisms by which sorafenib exerts anti-HCC effects \[75\].

Interestingly, interferon (IFN)-beta was reported to accumulates in the nucleus when poly (ADP-ribosyl)ation blocks its interaction with CRM1 \[60\], while interaction with SUMO (small ubiquitin-like modifier) promotes its export to cytoplasm by CRM1 \[61\]. p21 inhibits CRM1 by binding phosphorylated cyclin D, which promotes its nuclear accumulation \[40\].
influence these mechanisms and play a role in anti-hepatocarcinogenesis. Future uses of this drug should be pursued in light of this functional biological aspect.

REFERENCES

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061]

2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22335362 DOI: 10.1016/s0140-6736(11)6347-0]

3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687 [PMID: 16929323 DOI: 10.1038/ncrev1934]

4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma: incidence and risk factors. Gastroenterology 2004; 127: S35-S50 [PMID: 15508101]

5. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. deregulating SKP2 and its target, p21.

6. Forner A, Flores JM, García-Palencia P, Serrano M. Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001; 61: 6234-6238 [PMID: 11507077]

7. Shen KC, Heng H, Wang Y, Lu S, Liu G, Deng CX, Brooks SC, Wang YA. ATM and p21 cooperate to suppress aneuploidy and subsequent tumor development. Cancer Res 2005; 65: 8747-8753 [PMID: 16204044 DOI: 10.1158/0008-5472-can-05-1471]

8. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221 [PMID: 1552940 DOI: 10.1038/356215a0]

9. De la Cueva E, García-Cao I, Herranz M, López P, García-Palencia P, Flores JM, Serrano M, Fernández-Piqueras J, Martín-Caballero J. Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma. Oncogene 2006; 25: 4128-4132 [PMID: 16462758 DOI: 10.1038/sj.onc.1209432]

10. Wang YA, Elson A, Leder P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci USA 1997; 94: 14590-14595 [PMID: 9405657]

11. Chen CH, Wang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem Biophys Res Commun 2010; 403: 103-107 [PMID: 21040707 DOI: 10.1016/j.bbrc.2010.10.126]

12. Liu Y, Yeh N, Zhu XH, Leversha M, Cardoso-Cardo G, Ghosein R, Singh B, Holland E, Koff A. Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1). EMBO J 2007; 26: 4683-4693 [PMID: 17948060 DOI: 10.1038/sj.emboj.7601886]

13. Shi YZ, Hui AM, Takayama T, Li X, Cui X, Makachai M. Reduced p21(WAF1/CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas. Br J Cancer 2000; 83: 50-55 [PMID: 1083667 DOI: 10.1054/bjoc.2000.1310]

14. Hui AM, Kanay S, Sakamoto M, Touda H, Hirohashi S. Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas. Hepatology 1997; 25: 575-579 [PMID: 9049201 DOI: 10.1002/hep.510250314]

15. Furutani M, Arii S, Tanaka H, Mise M, Niwano M, Harada T, Higashitsuji H, Imamura M, Fujita J. Decreased expression of the CIP1/WAF1 gene in human hepatocellular carcinoma. Jpn J Cancer Res 2001; 92: 1412-1421, 1421.e1-5 [PMID: 11761710 DOI: 10.1111/j.1340-2594.2001.01099.x]

16. Wagayama H, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Yamamata T, Takase K, Nakano T. High expression of p21(WAF1/CIP1) is correlated with human hepatocellular carcinoma in patients with hepatitis C virus-associated chronic liver diseases. Pathol Int 2002; 52: 429-434 [PMID: 12055678]

17. Shiraki K, Wagayama H. Endogenous p21(WAF1/CIP1) expression in human hepatocellular carcinomas. Int J Mol Med 2003; 11: 563-566 [PMID: 12797108]

18. Abo HB, Chung EY, Kwun HJ, Jang KL. Transcriptional repression of p21(waf1) promoter by hepatitis B virus X protein via a p53-independent pathway. Gene 2001; 275: 139-147 [PMID: 11374165]

19. Huang Y, Tong S, Tai AW, Hussain M, Lok AS. Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21. Gastroenterology 2011; 141: 1412-1421, 1421.e1-5 [PMID: 21704589 DOI: 10.1053/
49. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, Bischoff R, Gietema JA, de Jong S. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest 2010; 120: 3594-3605 [PMID: 20881115 DOI: 10.1172/jcii41939]

50. Rössig L, Jadidi AS, Urbich C, Badorff C, Zeier MH, Dummer S. Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells. Mol Cell Biol 2001; 21: 5644-5657 [PMID: 11463845 DOI: 10.1128/mcb.21.16.5644-56

51. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21(Cip1)/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 2001; 3: 245-252 [PMID: 11231573 DOI: 10.1038/350860032]

52. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. The stress-activated protein kinase p38 alpha and INK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem 2002; 277: 29792-29802 [PMID: 12058028 DOI: 10.1074/jbc.M201299200]

53. Suzuki A, Tsutomi Y, Yamamoto N, Shibutani T, Akahane K. Mitochondrial regulation of cell death: mitochondria are essential for procaspase-3 p21 complex formation to resist Fas-mediated cell death. Mol Cell Biol 1999; 19: 3842-3847 [PMID: 10470167 DOI: 10.1128/mcb.19.21.3842-3847.1999]

54. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumura K, Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1)/WAF1 in monocytic differentiation. EMBO J 1999; 18: 1223-1234 [PMID: 10064589 DOI: 10.1093/emboj/18.5.1223]

55. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 83: 1021-1032 [PMID: 22200898 DOI: 10.1016/j.bcp.2011.12.016]

56. Fabbro M, Henderson BR. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 2003; 282: 59-69 [PMID: 12531692]

57. Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 2007; 17: 193-201 [PMID: 17317185 DOI: 10.1016/j.tcb.2007.02.003]

58. Gravina GL, Senapedis W, McCauley D, Baloglu E, Shacham S, Festuccia C. Nuclear-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol 2014; 7: 85 [PMID: 25476752 DOI: 10.1186/1304-01-0085-1]

59. Mao L, Yang Y. Targeting the nuclear transport machinery by rational drug design. Curr Pharm Des 2013; 19: 2318-2325 [PMID: 23082981]

60. Kanai M, Hanashiro K, Kim SH, Hanai S, Boulahs AH, Miwa M, Fukasawa K. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol 2005; 9: 1175-1183 [PMID: 15789113 DOI: 10.1038/ncb1268]

61. Santiago A, Li D, Zhao LY, Godsey A, Liao D. p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1. Mol Biol Cell 2015; 26: 2739-2752 [PMID: 23825024 DOI: 10.1091/mbc.E12-10-0771]

62. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 2002; 32: 1619-1628 [PMID: 12003838]

63. Walker CJ, Oaks JK, Santanhann N, Naviam P, Harb JG, Ferencak G, Ellis JJ, Landesman Y, Friedlander S, Shacham S, Kauffman MG, Merloz P, Keeling DI, Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 2007; 17: 193-201 [PMID: 17317185 DOI: 10.1016/j.tcb.2007.02.003]

64. Santachiari A, Di M, Zoli MD, Godsey A, Liu D. p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1. Mol Biol Cell 2015; 26: 2739-2752 [PMID: 23825024 DOI: 10.1091/mbc.E12-10-0771]

65. Huang WY, Yue L, Qiu WS, Wang LW, Zhou XH, Sun YJ. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 2002; 32: 1619-1628 [PMID: 12003838]

66. Walker CJ, Oaks JK, Santanhann N, Naviam P, Harb JG, Ferencak G, Ellis JJ, Landesman Y, Friedlander S, Shacham S, Kauffman MG, Merloz P, Keeling DI, Hutten S, Kehlenbach RH. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 2007; 17: 193-201 [PMID: 17317185 DOI: 10.1016/j.tcb.2007.02.003]

67. Santachiari A, Di M, Zoli MD, Godsey A, Liu D. p53 SUMOylation promotes its nuclear export by facilitating its release from the nuclear export receptor CRM1. Mol Biol Cell 2015; 26: 2739-2752 [PMID: 23825024 DOI: 10.1091/mbc.E12-10-0771]
Winkler J, Ori A, Holzer K, Sticht C, Dauch D, Eiteneuer EM, Beck M, Singer S. Prosurvival function of the cellular apoptosis susceptibility/importin-α transport cycle is repressed by p53 in liver cancer. *Hepatology* 2014; 60: 884-895 [PMID: 24799195 DOI: 10.1002/hep.27207]

Monecke T, Dickmanns A, Ficner R. Allosteric control of the exportin CRM1 unraveled by crystal structure analysis. *FEBS J* 2014; 281: 4179-4194 [PMID: 24823279 DOI: 10.1111/febs.12842]

Azmi AS, Al-Katib A, Aboukameel A, McCauley D, Kauffman M, Shacham S, Mohammad RM. Selective inhibitors of nuclear export for the treatment of non-Hodgkin’s lymphomas. *Haematologica* 2013; 98: 1098-1106 [PMID: 23403316 DOI: 10.3324/haematol.2012.074781]

Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukemia and acute myeloid leukemia. *Br J Haematol* 2013; 161: 117-127 [PMID: 23373539 DOI: 10.1111/bjh.12231]

Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas D, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC. Selective inhibitors of nuclear export show that CRM1/ XPO1 is a target in chronic lymphocytic leukemia. *Blood* 2012; 120: 4621-4634 [PMID: 23034282 DOI: 10.1182/blood-2012-05-429506]

Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon R. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. *Blood* 2012; 120: 1765-1773 [PMID: 22677130 DOI: 10.1182/blood-2012-04-423160]

Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnotto A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghorbii I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. *Leukemia* 2014; 28: 155-165 [PMID: 23588715 DOI: 10.1038/leu.2013.115]

Zheng Y, Gery S, Sun H, Shacham S, Kauffman M, Koeffler HP. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. *Cancer Chemother Pharmacol* 2014; 74: 487-495 [PMID: 25030088 DOI: 10.1007/s00280-014-2495-8]

Dudgeon C, Peng R, Wang P, Sebastiani A, Yu J, Zhang L. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. *Oncogene* 2012; 31: 4848-4858 [PMID: 22286758 DOI: 10.1038/onc.2011.644]

Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. *Nat Genet* 1995; 9: 41-47 [PMID: 7704023 DOI: 10.1038/ng0195-41]

Frahm T, Hauser H, Köster M. IFN-type-I-mediated signaling is regulated by modulation of STAT2 nuclear export. *J Cell Sci* 2006; 119: 1092-1104 [PMID: 16507591 DOI: 10.1242/jcs.02822]

Thompson MD, Dar MJ, Monga SP. Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin. *J Hepatol* 2011; 54: 506-512 [PMID: 21093092 DOI: 10.1016/j.jhep.2010.07.020]

Chuma M, Terashita K, Sakamoto N. New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions. *Hepatol Res* 2014; Epub ahead of print [PMID: 25472913 DOI: 10.1111/hepr.12459]
